Graphite Bio, Inc. (GRPH) Stock Price, Financial Report, & Fundamental Analysis
NASDAQ:GRPHGraphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. It offers GPH101, a gene-edited autologous hematopoietic stem cell product candidate to directly correct the mutation that causes sickle cell disease and restore normal adult hemoglobin expression; GPH201 for the treatment of X-linked severe combined immunodeficiency syndrome; and GPH301, a product candidate for the treatment of Gaucher disease, a genetic disorder that results in a deficiency in the glucocerebrosidase enzyme.
(0.7)
Graphite Bio, Inc. Fundamental Analysis
Strength
| Analysis | # |
|---|---|
Net Income GrowthGRPH has had growing net income for the last 2 years |
|
Price to Book (PBV) RatioUndervalued price-to-book. GRPH stock price is under 1x the price-to-book value. |
|
Debt-Equity Ratio (DER)GRPH equity is higher than it's debt. |
Weakness
| Analysis | # |
|---|---|
Market CapSmall market capitalization. Market capitalization is less than 2bn USD |
|
Revenue GrowthGRPH has never had growing revenue. |
|
Net IncomeGRPH never has positive net income for 2 years. |
|
Dividend YieldGRPH has low dividend yield (0%). |
|
Return of AssetsGRPH has low return of asset (-22.83%). |
|
Return of EquityGRPH has low return of equity (-21.84%). |
|
RevenueGRPH never has positive revenue for 2 years. |
|
Return of Invested CapitalGRPH has low ROIC. |
Competitors
Graphite Bio, Inc. Financials
Financial statements are written records that convey the business activities and the financial performance of a company. Financial statements include the balance sheet, income statement, and statement of cash flow.
Income Statement
Also known as the profit and loss (P&L) statement or the statement of revenue and expense, the income statement primarily focuses on the company’s revenue and expenses during a particular period.
- Revenue
- 0 USD
- Cost
- 0 USD
- Net Income
- 0 USD
- Profit Margin
- 0%
Cashflow Statement
A cash flow statement is a financial statement that provides aggregate data regarding all cash inflows a company receives from its ongoing operations and external investment sources. It also includes all cash outflows that pay for business activities and investments during a given period.
- Free Cash Flow
- -58,592,000 USD
Balance Sheet
Liquidity & Solvency
Solvency refers to an company's capacity to meet its long-term financial commitments. Liquidity refers to an company's ability to pay short-term obligations. The term also refers to a company's capability to sell assets quickly to raise cash.
Short Term Liabilities
| Quick Ratio | 2156.8% |
Long Term Liabilities
| Liquidity/Current Ratio | 2207.13% |
Dividend
| Dividend Yield | 0% |
| Dividend Payout Ratio (DPR) | 0% |
| Dividend Payout Ratio (DPR) | 0% |
| Dividend per Share | 0,00 USD |
Financial Ratios
| Price to Earning (PER) | 0.6x |
| Price to Earning-Growth (PEG) | 0x |
| Price to Book Value (PBV) | 0x |
| Liquidity/Current Ratio | 2207.13% |
| Cash Ratio | 416.97% |
| Debt Ratio | 5.49% |
| Debt-Equity Ratio (DER) | 5.81% |
| Net Profit Margin (NPM) | 0% |
| Return of Assets (ROA) | -22.83% |
| Return of Equity (ROE) | -21.84% |
| Return on Capital Employed (ROCE) | -30.45% |
| Days of Sales Outstanding (DSO) | 0 |
| Days of Inventory Outstanding (DIO) | 0 |
| Days Payable Outstanding (DPO) | 0 |
| Operating Cycle (OC) | 0 |
| Cash Conversion Cycle (CCC) | 0 |
Graphite Bio, Inc. Executives
CEO
- CEO Name
- Dr. Joshua Lehrer-Graiwer FAC
Management
Graphite Bio, Inc. Profile
About Graphite Bio, Inc.
Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. It offers GPH101, a gene-edited autologous hematopoietic stem cell product candidate to directly correct the mutation that causes sickle cell disease and restore normal adult hemoglobin expression; GPH201 for the treatment of X-linked severe combined immunodeficiency syndrome; and GPH301, a product candidate for the treatment of Gaucher disease, a genetic disorder that results in a deficiency in the glucocerebrosidase enzyme. The company was formerly known as Integral Medicines, Inc., and changed its name to Graphite Bio, Inc. in August 2020. Graphite Bio, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.
Additional Information
- Company name
- Graphite Bio, Inc.
- Symbol
- NASDAQ:GRPH
- Exchange
- NASDAQ Global Market
- Industry
- Biotechnology
- Sector
- Healthcare
- Address
-
279 East Grand Avenue
South San Francisco
CA
US
94080 - Website
- https://www.graphitebio.com